Modality
mRNA
MOA
PARPi
Target
TIGIT
Pathway
Tau
ETEpilepsy
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
~Feb 2017
→ ~May 2018
NDA/BLA
Aug 2018
→ Oct 2028
NDA/BLACurrent
NCT05334731
800 pts·Epilepsy
2018-08→2028-10·Not yet recruiting
800 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-122.5y awayPh3 Readout· Epilepsy
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2028-10-12 · 2.5y away
Epilepsy
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05334731 | NDA/BLA | Epilepsy | Not yet recr... | 800 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |